Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNYSE:ENOVNASDAQ:NVCRNASDAQ:SSII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$19.09-2.1%$13.92$8.89▼$24.50$827.67MN/A499,635 shs454,762 shsENOVEnovis$31.86-1.3%$33.24$29.13▼$49.83$1.82B1.71832,306 shs1.37 million shsNVCRNovoCure$17.55-3.6%$17.46$14.17▼$34.13$1.96B0.741.18 million shs1.35 million shsSSIISS Innovations International$3.54-9.2%$0.00$0.32▼$22.42$755.06MN/A38,467 shs77,511 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics-2.05%+0.05%+48.68%+30.13%+1,908,999,900.00%ENOVEnovis-1.33%+0.22%-12.01%-13.92%-29.43%NVCRNovoCure-3.57%+3.24%+2.63%-9.95%-17.41%SSIISS Innovations International-9.23%-41.00%-64.78%+353,999,900.00%+353,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/AENOVEnovis2.9346 of 5 stars3.42.00.00.02.31.71.9NVCRNovoCure3.896 of 5 stars3.34.00.04.51.41.70.0SSIISS Innovations InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.73Moderate Buy$23.1321.14% UpsideENOVEnovis 2.80Moderate Buy$58.0082.05% UpsideNVCRNovoCure 2.67Moderate Buy$32.8387.08% UpsideSSIISS Innovations International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BBNX, ENOV, NVCR, and SSII Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/14/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.005/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.004/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.004/2/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$69.83M11.85N/AN/AN/A∞ENOVEnovis$2.15B0.85$4.64 per share6.86$62.66 per share0.51NVCRNovoCure$621.71M3.15N/AN/A$3.39 per share5.18SSIISS Innovations International$22.13M30.97N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta BionicsN/AN/A0.00∞N/AN/AN/AN/AN/AENOVEnovis-$33.26M-$13.95N/A9.99N/A-5.95%4.39%2.80%8/6/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)SSIISS Innovations InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ALatest BBNX, ENOV, NVCR, and SSII EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million3/25/2025Q4 2024BBNXBeta Bionics-$0.42-$1.82-$1.40-$2.72$20.01 million$20.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ASSIISS Innovations InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/AN/AN/AENOVEnovis0.402.271.12NVCRNovoCure0.271.491.44SSIISS Innovations InternationalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AENOVEnovis98.45%NVCRNovoCure84.61%SSIISS Innovations InternationalN/AInsider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AENOVEnovis2.70%NVCRNovoCure5.52%SSIISS Innovations InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/AENOVEnovis6,80057.12 million55.49 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableSSIISS Innovations International4193.60 millionN/AN/ABBNX, ENOV, NVCR, and SSII HeadlinesRecent News About These CompaniesSS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic SystemMay 27, 2025 | prismmediawire.comSS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic SystemMay 27, 2025 | globenewswire.comSS Innovations Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prismmediawire.comSS Innovations Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBNX, ENOV, NVCR, and SSII Company DescriptionsBeta Bionics NASDAQ:BBNX$19.09 -0.40 (-2.05%) As of 06/13/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Enovis NYSE:ENOV$31.86 -0.43 (-1.33%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$31.91 +0.05 (+0.16%) As of 06/13/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.NovoCure NASDAQ:NVCR$17.55 -0.65 (-3.57%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$17.57 +0.02 (+0.11%) As of 06/13/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.SS Innovations International NASDAQ:SSII$3.54 -0.36 (-9.23%) As of 06/13/2025 04:00 PM EasternAVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
